



Appendix 4C

Quarter Ended 31 December 2017

San Diego, California and Sydney, Australia (Thursday, 1 February 2018 - AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 December 2017. The Appendix 4C is unaudited.

Fourth Quarter 2017 Highlights

During the fourth quarter of 2017, the Company continued to rebuild the market for bioresorbable coronary scaffolds (BRS), a market which has been severely impacted by the withdrawal of a competitor’s product in 2017 and the negative publicity around that product’s safety. We released additional clinical evidence supporting the long-term safety of the Fantom® bioresorbable scaffold, we engaged with key physician leaders to educate them on Fantom’s unique properties and safety record, and we continued our commercial expansion in existing accounts and into new accounts.

Highlights from the quarter include:

- **Commercial Sales Force** – We welcomed our first two sales managers to REVA on November 1, 2017. We added two additional sales managers on January 1, 2018 and our fifth sales manager will join on February 1, 2018. Our small commercial team is focused on differentiating Fantom’s features, benefits and safety track record from other CE Mark approved BRS devices to ensure successful adoption of the Fantom scaffold in select accounts in Germany, Switzerland, and Austria, which are the initial countries identified as part of REVA’s targeted launch. Our focused sales efforts and marketing strategies are expected to increase volume and reorder rates throughout 2018.
- **Clinical Data** - The Company released new data at the Transcatheter Cardiovascular Therapeutics (TCT) conference in October 2017. Clinical outcomes were reported for an interim data set of 125 patients followed through 24 months. Findings included a low rate of Major Adverse Cardiac Events (“MACE”) of 5.6%. REVA previously reported a MACE rate of 4.2% through 12 months for the complete 240-patient data set. The 24-month outcomes demonstrate a sustained safety profile for Fantom. The data were presented in an oral presentation by Dr. James B. Hermiller Jr., from the Heart Center of Indiana in Indianapolis, Indiana and in a moderated poster session by trial investigator, Dr. Ricardo A. Costa, from Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil.
- **Product Development** – The Company announced plans to expand its product portfolio with Fantom Encore at the TCT conference in October 2017. Fantom Encore has a market leading 95-micron strut thickness in the 2.5-millimeter diameter size. REVA anticipates CE Mark approval for Fantom Encore in the first half of 2018.

Appendix 4C

As of 31 December 2017, the Company’s cash balance was US \$18.5 million. The current quarter-end cash balance is a decrease of US \$4.1 million from the 30 September 2017 balance of US \$22.6 million reflecting US \$4.0 million

in disbursements related to normal operating activities, purchases of US \$42,000 of capital equipment, offset slightly by US \$99,000 in receipts from customers. As of 31 December 2017, the Company also had \$1.5 million in investment securities.

The Company currently plans to file its Form 10-K Annual Report with the U.S. Securities and Exchange Commission and with the Australian Securities Exchange on or before the due date of 16 March 2018. The Annual Report provides financial statements, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended 31 December 2017.

About Fantom

Fantom is a sirolimus-eluting bioresorbable scaffold (BRS) developed as an alternative to metallic stents for the treatment of coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, and then disappear (or “resorb”) from the body over a period of time. This resorption is intended to allow the return of natural movement and function of the artery. Fantom is the only bioresorbable scaffold made from Tyrocore™, REVA’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently x-ray visible, making Fantom the first and only BRS that is visible under x-ray. Fantom is designed with thin struts while maintaining strength and with distinct ease-of-use features such as expansion with one continuous inflation.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead product, the Fantom bioresorbable scaffold, received European CE Mark on April 3, 2017 for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the U.S. and Europe.

Fantom, Fantom Encore, and Tyrocore are trademarks of REVA Medical, Inc.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on February 28, 2017, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

United States

Investor & Media Enquiries:

REVA Medical, Inc.
Brandi Roberts
Chief Financial Officer
+1 858-966-3003
Cheryl Liberatore
Director, Communications
+1 858-966-3045
ir@teamreva.com

Australia

Investor Enquiries:

Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

Australia

Media Enquiries:

Buchan Consulting
Rebecca Wilson
+61 3 9866 4722

[Appendix to Follow]

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

REVA Medical, Inc.

ABN

ARBN 146 505 777

Quarter ended ("current quarter")

31 December 2017

Consolidated statement of cash flows	Current quarter (Q4) \$'000 USD	Year to date (12 months) \$'000 USD
1. Cash flows from operating activities		
1.1 Receipts from customers	99	140
1.2 Payments for		
(a) research and development	(1,158)	(5,857)
(b) product manufacturing and operating costs	(485)	(1,262)
(c) advertising and marketing	(26)	(118)
(d) leased assets	0	0
(e) staff costs	(1,727)	(8,884)
(f) administration and corporate costs	(747)	(2,937)
1.3 Dividends received (see note 3)	0	0
1.4 Interest received	17	50
1.5 Interest and other costs of finance paid	0	0
1.6 Income taxes paid	0	0
1.7 Government grants and tax incentives	0	0
1.8 Other (provide details if material)	0	0
1.9 Net cash from / (used in) operating activities	(4,027)	(18,868)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(42)	(377)
(b) businesses (see item 10)	0	0
(c) investments	0	0
(d) intellectual property	0	0
(e) other non-current assets	0	0

Consolidated statement of cash flows	Current quarter (Q4) \$'000 USD	Year to date (12 months) \$'000 USD
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	0	0
(b) businesses (see item 10)	0	0
(c) investments	0	(1,470)
(d) intellectual property	0	0
(e) other non-current assets	0	0
2.3 Cash flows from loans to other entities	0	0
2.4 Dividends received (see note 3)	0	0
2.5 Other (provide details if material)	0	0
2.6 Net cash from / (used in) investing activities	(42)	(1,847)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	0	0
3.2 Proceeds from issue of convertible notes	0	47,100
3.3 Proceeds from exercise of share options	0	93
3.4 Transaction costs related to issues of shares, convertible notes or options	0	(2,115)
3.5 Proceeds from borrowings	0	0
3.6 Repayment of borrowings	0	0
3.7 Transaction costs related to loans and borrowings	0	0
3.8 Dividends paid	0	0
3.9 Other (repurchase of common stock)	0	(12,493)
3.10 Net cash from / (used in) financing activities	0	32,585

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	22,613	6,674
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(4,027)	(18,868)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(42)	(1,847)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	0	32,585
4.5 Effect of movement in exchange rates on cash held	0	0
4.6 Cash and cash equivalents at end of quarter	18,544	18,544

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter (12/31/2017) \$'000 USD	Previous quarter (9/30/2017) \$'000 USD
5.1 Bank balances	14,005	741
5.2 Call deposits	4,539	21,872
5.3 Bank overdrafts	0	0
5.4 Other (provide details)	0	0
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	18,544	22,613

6. Payments to directors of the entity and their associates

	Current quarter (Q4) \$'000 USD
6.1 Aggregate amount of payments to these parties included in item 1.2	83
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	0
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

Australian Director fees (1 non-executive directors)	\$USD 13
U.S. Director fees (5 non-executive directors)	\$USD 70

7. Payments to related entities of the entity and their associates

	Current quarter \$'000 USD
7.1 Aggregate amount of payments to these parties included in item 1.2	0
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	0
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

--

8. Financing facilities available
Add notes as necessary for an understanding of the position

	Total facility amount at quarter end \$'000 USD	Amount drawn at quarter end \$'000 USD
8.1 Loan facilities	0	0
8.2 Credit standby arrangements	0	0
8.3 Other (please specify)	0	0
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--

